US2004062716A1PendingUtilityA1

Buccal, polar and non-polar spray of capsule

Assignee: NOVADEL PHARMA INCPriority: Oct 1, 1997Filed: Sep 17, 2003Published: Apr 1, 2004
Est. expiryOct 1, 2017(expired)· nominal 20-yr term from priority
Inventors:Harry Dugger
A61K 9/0056A61K 47/06A61K 47/14A61K 9/124A61P 1/08A61K 31/421A61K 31/27A61K 31/7076A61K 9/006A61K 31/4178A61K 31/197A61K 31/433A61K 38/13A61K 47/44A61K 31/138A61K 31/085A61K 31/137
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Buccal aerosol sprays or capsule using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprises formulation I: polar solvent 37-98.58%, active compound 0.005-55%, optionally containing flavoring agent 0.1-10%.

Claims

exact text as granted — not AI-modified
1 . A buccal polar pump spray composition for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent said composition comprising in weight % of total composition: polar solvent 37-98.58%, active compound 0.005-55% 
 wherein the active compound is selected from the group consisting of biologically active peptides, central nervous system active amines, sulfonyl ureas, antibiotics, antifungals, antivirals, sleep inducers, antiasthmatics, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostoglandins, bronchial dilators selected from the group consisting of terbutaline, and theophylline.    
     
     
         2 . The composition of  claim 1  additionally comprising, by weight of total composition: flavoring agent 0.1-10%.  
     
     
         3 . The composition of  claim 1  comprising: polar solvent 60.9-97.06%, active compound 0.01-40%, flavoring agent 0.75-7.5%.  
     
     
         4 . The composition of  claim 1  wherein the polar solvent is selected from the group consisting of low molecular weight polyethylene-glycols (PEG) of 400-1000 MW, C 2 -C 8  mono- and poly-alcohols, and alcohols of C 7 -C 18  hydrocarbons of a linear or branched configuration.  
     
     
         5 . The composition of  claim 1  wherein the solvent is aqueous polyethylene glycol.  
     
     
         6 . The composition of  claim 1  wherein the solvent comprises aqueous ethanol.  
     
     
         7 . The composition of  claim 1  wherein the active compound is selected from the group consisting of cyclosporin, clozapine, zidevudine, erythromycin, odansetron, cimetidine, phenytoin, carboprost thromethamine, and valerian in their nonionized form or as the pharmaceutically acceptable salts thereof.  
     
     
         8 . The composition of  claim 2  wherein the flavoring agents are selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners and combinations thereof.  
     
     
         9 . The composition of  claim 2  of the formulation: polar solvent 75-85%, cyclosporin 15-25%, flavoring agent 0.1-5%.  
     
     
         10 . The composition of  claim 2  of the formulation: polar solvent 19-90%, odansitron hydrochloride 2.5-15%, flavoring agent 1-10%.  
     
     
         12 . A method of administering a pharmacologically active compound to a mammal in needed of same, by spraying the oral mucosa of said mammal with a composition of  claim 1 .  
     
     
         13 . The method of  claim 12  wherein the amount of spray administered is predetermined.

Join the waitlist — get patent alerts

Track US2004062716A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.